704 reports of this reaction
5.0% of all TENOFOVIR DISOPROXIL FUMARATE TABLETS reports
#3 most reported adverse reaction
VIRAL MUTATION IDENTIFIED is the #3 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE TABLETS, manufactured by Chartwell RX, LLC.. There are 704 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE TABLETS to VIRAL MUTATION IDENTIFIED. This represents approximately 5.0% of all 14,129 adverse event reports for this drug.
Patients taking TENOFOVIR DISOPROXIL FUMARATE TABLETS who experience viral mutation identified should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIRAL MUTATION IDENTIFIED is moderately reported among TENOFOVIR DISOPROXIL FUMARATE TABLETS users, representing a notable but not dominant share of adverse events.
In addition to viral mutation identified, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE TABLETS:
The following drugs have also been linked to viral mutation identified in FDA adverse event reports:
VIRAL MUTATION IDENTIFIED has been reported as an adverse event in 704 FDA reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIRAL MUTATION IDENTIFIED accounts for approximately 5.0% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE TABLETS, making it one of the most commonly reported side effect.
If you experience viral mutation identified while taking TENOFOVIR DISOPROXIL FUMARATE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.